Fenglei Huang

ORCID: 0000-0002-0642-9401
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • High-Velocity Impact and Material Behavior
  • Venous Thromboembolism Diagnosis and Management
  • Blood Coagulation and Thrombosis Mechanisms
  • HIV/AIDS drug development and treatment
  • Energetic Materials and Combustion
  • Hepatitis C virus research
  • Cardiac Arrhythmias and Treatments
  • Structural Response to Dynamic Loads
  • Analytical Methods in Pharmaceuticals
  • Biochemical and Molecular Research
  • Pharmacogenetics and Drug Metabolism
  • Receptor Mechanisms and Signaling
  • Hydrogen Storage and Materials
  • Atrial Fibrillation Management and Outcomes
  • Thermal and Kinetic Analysis
  • Combustion and Detonation Processes
  • Phenothiazines and Benzothiazines Synthesis and Activities
  • Ammonia Synthesis and Nitrogen Reduction
  • HIV Research and Treatment
  • Metal-Organic Frameworks: Synthesis and Applications
  • Chemical synthesis and alkaloids
  • Pharmacological Effects and Toxicity Studies
  • Drug Transport and Resistance Mechanisms
  • Pharmaceutical studies and practices
  • Hybrid Renewable Energy Systems

Boehringer Ingelheim (United States)
2014-2025

Beijing Institute of Technology
2010-2025

China Pharmaceutical University
2024

Boehringer Ingelheim (India)
2020

University of Florida
1998-2018

Boehringer Ingelheim (Australia)
2017

Columbus Oncology and Hematology Associates
2017

Boehringer Ingelheim (Germany)
2014

Janssen (United States)
2002

Johnson & Johnson (United States)
2002

Ming‐Chih Lin Leonardo R. Brandão Matteo Luciani Lisa Bomgaars Elizabeth Chalmers and 88 more Lesley Mitchell Ildar Nurmeev Anjali Sharathkumar Pavel Svirin Kirill Gorbatikov Igor Tartakovsky Monika Simetzberger Fenglei Huang Zhichao Sun Jörg Kreuzer Savion Gropper Paul A. Reilly Martina Brueckmann Manuela Albisetti Ildar Nurmeev А. И. Сафина Ondřej Zapletal Leonardo R. Brandão Tomáš Kuhn Tomáš Votava Judy Felgenhauer Anjali Sharathkumar Pavel Svirin Ali Amid Ming‐Chih Lin Kirill Gorbatikov Paola Saracco Csongor Kiss Susan Halimeh Madlen Reschke Beate Wulff Michèle David Zbyněk Novák I.I. Trunina Manuela Albisetti Tony Frisk Heidi Glosli Andreas H. Groll O. Lvova İlgen Şaşmaz Darintr Sosothikul Virginija Žilinskaitė Erin Cockrell V. A. Digtyar I Hadačová Sauli Palmu Anjali Pawar Joyce Maria Annichino Bizzacchi Ümran Çalışkan Tıraje Celkan Dmytro Dmytrіiev Colleen Druzgal Graciela Elena Antonis Kattamis Ramazan Kavakli Christoph Male Nihal Özdemir An Van Damme T. N. Zvereva Aanen Aarli Rogelio Alejandro Paredes Aguilera Selin Aytaç Jorge David Aivazoglou Carneiro Antonio Chistolini M.G. Mazzucconi Fernando F. Corrales‐Medina Françis Couturaud Stacey E Croteau Cameron C. Trenor Michael Damgaard Natalia Dixon A.N. Galustyan Jiří Hák Marianne Hoffmann Alphan Küpesiz Veerle Labarque Chris Van Geet Ming‐Chih Lin Yun‐Ching Fu Sandra Regina Loggetto Veerle Mondelaers Irena Odri-Komazec Shoshana Revel‐Vilk Julián Sevilla Luciano Fuzzato Silva José Kerr Saraiva Fernando Montes‐Tapia Wendy Woods‐Swafford

10.1016/s2352-3026(20)30368-9 article EN The Lancet Haematology 2020-12-05

The renal secretion of many drugs is facilitated by membrane transporters, including organic cation transporter 2, multidrug and toxin extrusion protein 1/2-K anion transporters 1 3. Inhibition these can reduce excretion thereby pose a safety risk. Assessing the risk inhibition investigational remains key focus in evaluation drug-drug interactions (DDIs). Current methods to predict DDI are based on generating vitro data followed clinical assessment using recommended exogenous probe substrate...

10.1007/s40262-024-01385-0 article EN cc-by-nc Clinical Pharmacokinetics 2024-06-01

To assess the safety and pharmacokinetic pharmacodynamic characteristics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibitor, after single- repeated-dose administration.The single-dose study included open-label administration 200 mg 135585 in healthy volunteers, while multiple-dose study, we carried out randomized, double-blind 5-200 or placebo once daily over 14 days patients with type 2 diabetes (T2DM). Assessments 11β-HSD1 inhibition liver (urinary...

10.1111/dom.12635 article EN Diabetes Obesity and Metabolism 2016-01-22

10.1016/j.ijsolstr.2020.02.013 article EN International Journal of Solids and Structures 2020-02-07

Essentials Dabigatran etexilate may provide a new treatment option for pediatric venous thromboembolism. Children aged 1 to < 12 years were given dabigatran in an open-label, single-arm study. The pharmacokinetic-pharmacodynamic relationship was similar that seen adult patients. There no serious adverse events, bleeding events or recurrent thromboembolism.Background current standard-of-care treatments thromboembolism (VTE) have limitations. (DE), direct thrombin inhibitor, offer alternative...

10.1111/jth.13847 article EN cc-by-nc Journal of Thrombosis and Haemostasis 2017-09-18

Abstract Venous thromboembolism (VTE) is more frequent in infants than older children. Treatment guidelines children are adapted from adult VTE data, but do not currently include direct oral anticoagulant use. Dabigatran etexilate (DE) use the paediatric population with therefore requires verification. We investigated pharmacokinetic/pharmacodynamic (PK/PD) relationship, safety and tolerability of DE liquid formulation (OLF) (aged &lt; 12 months) who had completed standard treatment an...

10.1160/th17-06-0429 article EN Thrombosis and Haemostasis 2017-01-01

Background: Pharmacokinetic drug–drug interactions (DDIs) can be caused by the effect of a pharmaceutical compound on activity one or more subtypes Cytochrome P450 (CYP) family, UDP-glucuronosyltransferases (UGTs), and/or transporters. As number therapeutic areas with polypharmacy has increased, interest grown in assessing risk DDIs during early phases drug development. Various lines research have led to improved mathematical models predict DDIs, culminating Food and Drug Administration’s...

10.3390/pharmaceutics17020159 article EN cc-by Pharmaceutics 2025-01-24

Receptor binding studies were performed on 24 soft anticholinergic agents and 5 conventional using 4 cloned human muscarinic receptor subtypes. The measured pK i values of the ranged from 6.5 to 9.5, with majority being in range 7.5 8.5. Strong correlation was observed between is determined here pA 2 earlier guinea pig ileum contraction assays. corresponding coefficients (r 2) 0.80, 0.73, 0.81, 0.78 for i(m1), i(m2), i(m3), i(m4), respectively. Quantitative structure-activity relationship...

10.1208/ps030430 article EN AAPS PharmSci 2001-12-01

Background An increasing number of studies suggest that environmental pollution may increase the risk vitamin D deficiency (VDD). However, less is known about arsenic (As) exposure and VDD, particularly in Chinese pregnant women. Objectives This study examines correlations different urinary As species with serum 25 (OH) VDD prevalence. Methods We measured arsenite (As 3+ ), arsenate 5+ monomethylarsonic acid (MMA), dimethylarsinic (DMA) levels 25(OH)D 2 , 3 25(OH) 391 women Tianjin, China....

10.3389/fpubh.2024.1371920 article EN cc-by Frontiers in Public Health 2024-04-17

Purpose: This study aimed to explore the association between N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) single nucleotide polymorphisms (SNPs) and gestational diabetes mellitus (GDM) modification of relationship by folate vitamin B 12 .Methods: A cross-sectional involving 1303 pregnant women (262 GDM 1041 non-GDM) was performed in Tianjin, China.Nine SNPs N6AMT1 were genotyped, serum folate, , homocysteine (Hcy) levels measured.The logistic regression models determined odds ratios...

10.2147/dmso.s451045 article EN cc-by-nc Diabetes Metabolic Syndrome and Obesity 2024-04-01

The hypervelocity impact experiments of spherical LY12 aluminum projectile diameter 6.4 mm on target thickness 23 have been conducted using a two-stage light gas gun. velocity the is 5.2, 5.7, and 6.3 km/s, respectively. experimental results show that plasma phase transition appears under current experiment conditions, expansion consists accumulation, equilibrium, attenuation. characteristic parameters decrease as expands outward are proportional with third power velocity, i.e., (Te, ne) ∝...

10.1063/1.4895592 article EN Physics of Plasmas 2014-09-01

Background Physiological age-related changes in the haemostatic and coagulation systems result differing anticoagulant assay responses to standard anticoagulants. Therefore, we investigated response of assays dabigatran etexilate (DE) children compared with adults. Objective This article assesses relationship between plasma concentration results across age groups Patients Methods Data from three clinical trials which received DE following care for venous thromboembolism were data adult...

10.1055/s-0038-1668132 article EN cc-by-nc-nd Thrombosis and Haemostasis 2018-08-15
Coming Soon ...